AML is/was the fastest pathway to market. I think it's unlikely they abandon those plans. They only caveat being that with the delays caused by IV formulation there may be a faster pathway to market via cardioprotection.
Would be interesting to know what was discussed with the FDA last November.
General Comments / Chat, page-7156
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.030(1.78%) |
Mkt cap ! $284.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.65 | $90.99K | 54.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4198 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 3391 | 2 |
View Market Depth
| Last trade - 11.59am 03/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |